Race To Develop Oral MS Therapy Heats Up As Novartis Releases Data Results
This article was originally published in The Pink Sheet Daily
Executive Summary
In Phase II studies, 77% of patients treated with Novartis' FTY720 remained relapse free after two years.
You may also be interested in...
Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says
Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.
Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says
Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.
Novartis’ Oral MS Drug Strong In Three-year Phase II Data
Side effects rang alarms early on, but disappeared over time.